College of Pharmacy, Southern Medical University, Guangzhou, China; Department of Pharmacy, Chinese PLA General Hospital, Beijing, China.
Department of Pharmacy, Chinese PLA General Hospital, Beijing, China.
Comput Biol Med. 2022 May;144:105389. doi: 10.1016/j.compbiomed.2022.105389. Epub 2022 Mar 9.
Huanglian Jiedu Decoction (HLJDD) is a classical herbal formula with potential efficacy in the treatment of sepsis. However, the main components and potential mechanisms of HLJDD remain unclear. This study aims to initially clarify the potential mechanism of HLJDD in the treatment of sepsis based on network pharmacology and molecular docking techniques.
The principal components and corresponding protein targets of HLJDD were searched on TCMSP, BATMAN-TCM and ETCM and the compound-target network was constructed by Cytoscape3.8.2. Sepsis targets were searched on OMIM and DisGeNET databases. The intersection of compound target and disease target was obtained and the coincidence target was imported into STRING database to construct a PPI network. We further performed GO and KEGG enrichment analysis on the targets. Finally, molecular docking study was approved for the core target and the active compound.
There are 257 nodes and 792 edges in the component target network. The compounds with a higher degree value are quercetin, kaempferol, and wogonin. The protein with a higher degree in the PPI network is JUN, RELA, TNF. GO and KEGG analysis showed that HLJDD treatment of sepsis mainly involves positive regulation of transcription from RNA polymerase II promoter, negative regulation of apoptosis process, response to hypoxia and other biological processes. The signaling pathways mainly include PI3K-AKT, MAPK, TNF signaling pathway. The molecular docking results showed that quercetin, kaempferol and wogonin have higher affinity with JUN, RELA and TNF.
This study reveals the active ingredients and potential molecular mechanism of HLJDD in the treatment of sepsis, and provides a reference for subsequent basic research.
黄连解毒汤(HLJDD)是一种具有治疗脓毒症潜力的经典中药方剂。然而,HLJDD 的主要成分和潜在机制仍不清楚。本研究旨在基于网络药理学和分子对接技术初步阐明 HLJDD 治疗脓毒症的潜在机制。
在 TCMSP、BATMAN-TCM 和 ETCM 上搜索 HLJDD 的主要成分和相应的蛋白靶点,并使用 Cytoscape3.8.2 构建化合物-靶标网络。在 OMIM 和 DisGeNET 数据库中搜索脓毒症靶点。获取化合物靶标和疾病靶标的交集,并将共同靶标导入 STRING 数据库构建 PPI 网络。进一步对靶标进行 GO 和 KEGG 富集分析。最后,对核心靶标和活性化合物进行分子对接研究。
在成分靶标网络中,有 257 个节点和 792 个边。度值较高的化合物有槲皮素、山奈酚和白杨素。PPI 网络中度值较高的蛋白为 JUN、RELA 和 TNF。GO 和 KEGG 分析表明,HLJDD 治疗脓毒症主要涉及 RNA 聚合酶 II 启动子的正调控转录、细胞凋亡过程的负调控、缺氧反应等生物学过程。信号通路主要包括 PI3K-AKT、MAPK、TNF 信号通路。分子对接结果表明,槲皮素、山奈酚和白杨素与 JUN、RELA 和 TNF 具有较高的亲和力。
本研究揭示了 HLJDD 治疗脓毒症的活性成分和潜在分子机制,为后续基础研究提供了参考。